About ERLOCIP ERLOTINIB 150MG TABLETS
Erlocip 150 Mg Tablets - Erlotinib Hydrochloride
Erlocip Tablets Contains Erlotinib And Its Available As : 100 Mg & 150 Mg Tablets...
Specification :-
- Product Name : Erlocip
- Content : Erlotinib Hcl
- Form : Tablets
- Strength : 100 Mg & 150 Mg
- Packing : Pack Of 30 Tablets
- Manufactured By : Cipla
Note :-Erlocip Is A Prescription Drug And Should Be Used Under Proper Medical Guidance And Advice. Do Not Share The Medicine With Others, Since They May Be Suffering From A Problem That Is Not Effectively Treated By This Drug................
Antineoplastic Action for Cancer CareERLOCIP functions as an EGFR inhibitor, targeting cancer cell growth and progression in non-small cell lung and advanced pancreatic cancer. Its mechanism blocks specific receptor pathways, slowing disease advancement and contributing to improved patient outcomes when prescribed appropriately.
Administration and Dosage GuidelinesTake ERLOCIP orally, either at least 1 hour before or 2 hours after food, to ensure optimal absorption. Dosage and treatment duration are prescribed and closely monitored by an oncologist, tailored to individual health needs and response to therapy.
Safety, Side Effects, and ContraindicationsWhile ERLOCIP offers significant benefits, side effects may include rash, diarrhea, fatigue, cough, and nausea. It is contraindicated in those hypersensitive to Erlotinib or any formulation component. Regular medical supervision is necessary to manage risks and adjust therapy.
FAQs of ERLOCIP ERLOTINIB 150MG TABLETS:
Q: How should ERLOCIP 150mg tablets be taken for best results?
A: Take ERLOCIP orally on an empty stomacheither one hour before or two hours after eatingas prescribed by your oncologist. Consistent dosing improves effectiveness and absorption.
Q: What is the main benefit of ERLOCIP in cancer treatment?
A: ERLOCIP acts as an EGFR inhibitor, slowing the progression of non-small cell lung cancer and advanced pancreatic cancer, thereby supporting improved clinical outcomes under medical supervision.
Q: When is ERLOCIP prescribed, and for which conditions?
A: ERLOCIP is indicated for locally advanced or metastatic non-small cell lung cancer and advanced pancreatic cancer, but only on the recommendation and prescription of an oncologist.
Q: What side effects should I be aware of while taking ERLOCIP?
A: Common side effects include rash, diarrhea, fatigue, cough, and nausea. Inform your physician immediately if these or any other unusual symptoms develop during treatment.
Q: Where should ERLOCIP tablets be stored for maximum shelf life?
A: Store ERLOCIP below 30C, protected from light and moisture, and keep the tablets in their original blister packaging to maintain their quality for up to 24 months.
Q: Who should avoid using ERLOCIP?
A: People with known hypersensitivity to Erlotinib or any ingredient in the formulation should not use ERLOCIP, as it may trigger adverse reactions.
Q: What process is followed for obtaining ERLOCIP tablets?
A: ERLOCIP is available only via prescription from an oncologist. Pharmacies can dispense it upon verifying the authorized prescription, ensuring safe and controlled usage.